Multivariate analysis to determine the prognostic effects of selected variables* on letters gained from baseline at (A) year 1 and (B) year 2 (only significant variables are shown)
| Coefficient | SE | Lower 95% CI | Upper 95% CI | p Value | |
|---|---|---|---|---|---|
| (A) Variables (year 1)† | |||||
| Switching to other treatments | −4.45 | 1.72 | −7.82 | −1.07 | 0.010 |
| Age at start of therapy | −0.27 | 0.05 | −0.37 | −0.16 | <0.001 |
| Baseline visual acuity score | −0.35 | 0.02 | −0.39 | −0.30 | 0.000 |
| Number of ophthalmoscopies and OCT (combined) | 0.28 | 0.06 | 0.16 | 0.40 | <0.001 |
| Constant | 40.33 | 4.51 | 31.48 | 49.17 | <0.001 |
| (B) Variables (year 2)‡ | |||||
| Number of injections (ranibizumab) | 0.32 | 0.11 | 0.12 | 0.53 | 0.002 |
| Number of ophthalmoscopies and OCT (combined) | 0.13 | 0.04 | 0.05 | 0.21 | 0.001 |
| Age at start of therapy | −0.28 | 0.07 | −0.41 | −0.15 | <0.001 |
| Baseline visual acuity score | −0.42 | 0.03 | −0.48 | −0.36 | <0.001 |
| Constant | 41.32 | 5.86 | 29.83 | 52.81 | <0.001 |
*The selected variables were the ones that were significantly associated with letters gained in the univariate regression analysis, including those that were tested using Pearson's correlation test and those that were tested for normality (continuous variables only), but only those that remained significant in the multivariate analysis are shown.
OCT, optical coherence tomography.
†Number of observations of the analysis was 1329; F-value: 64.31; R2=0.16.
‡Number of observations of the analysis was 968; F-value: 63.02; R2=0.21.